Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps
ACS Infectious Diseases · 10.05.2024 · 10 (5) · 1458-1482
DOI: 10.1021/acsinfecdis.4c00091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Infectious Diseases, online erschienen am 25.04.2024. Verfasst von Maëlle Duffey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Antibiotic Research & Development Partnership (GARDP), Chemin Camille-Vidart 15, 1202 Geneva, Switzerland. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacteria, Membrane Transport Proteins, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Efflux is a natural process found in all prokaryotic and eukaryotic cells that removes a diverse range of substrates from inside to outside. Many antibiotics are substrates of bacterial efflux pumps, and modifications to the structure or overexpression of efflux pumps are an important resistance mechanism utilized by many multidrug-resistant bacteria. Therefore, chemical inhibition of bacterial efflux to revitalize existing antibiotics has been considered a promising approach for antimicrobial chemotherapy over two decades, and various strategies have been employed. In this review, we provide an overview of bacterial multidrug resistance (MDR) efflux pumps, of which the resistance nodulation division (RND) efflux pumps are considered the most clinically relevant in Gram-negative bacteria, and describe over 50 efflux inhibitors that target such systems. Although numerous efflux inhibitors have been identified to date, none have progressed into clinical use because of formulation, toxicity, and pharmacokinetic issues or a narrow spectrum of inhibition. For these reasons, the development of efflux inhibitors has been considered a difficult and complex area of research, and few active preclinical studies on efflux inhibitors are in progress. However, recently developed tools, including but not limited to computational tools including molecular docking models, offer hope that further research on efflux inhibitors can be a platform for research and development of new bacterial efflux inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Antibiotic Research & Development Partnership (GARDP), Chemin Camille-Vidart 15, 1202 Geneva, Switzerland.
ORCID-Profile: Maëlle Duffey, Benjamin Blasco
Förderung
- Wellcome Trust
Zitieren
APA
Duffey, M., Jumde, R. P., da Costa, R. M. A., Ropponen, H. K., Blasco, B., & Piddock, L. J. V. (2024). Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps. ACS Infectious Diseases, 10(5), 1458-1482. https://doi.org/10.1021/acsinfecdis.4c00091
Vancouver
Duffey M, Jumde RP, da Costa RMA, Ropponen HK, Blasco B, Piddock LJV. Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps. ACS Infectious Diseases. 2024;10(5):1458-1482. doi:10.1021/acsinfecdis.4c00091
BibTeX
@article{Duffey2024,
author = {Duffey, Maëlle and Jumde, Ravindra P and da Costa, Renata M A and Ropponen, Henni-Karoliina and Blasco, Benjamin and Piddock, Laura J V},
title = {Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps},
journal = {ACS Infectious Diseases},
year = {2024},
volume = {10},
number = {5},
pages = {1458--1482},
doi = {10.1021/acsinfecdis.4c00091}
}
EUVIMED